Drugs / Faceptor
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05301530 | May 2019 → Aug 2020 | female breast carcinoma | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05301010 | Feb 2018 → Feb 2021 | female breast carcinoma | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Faceptor | “Patients received a loading dose of Faceptor 8 mg/kg IV + docetaxel 75 mg/m\^2 IV on Cycle 1 followed by Faceptor 6 mg/kg IV + docetaxel 75 mg/m\^2 IV on the next 5 cycles...” NCT05301530 ↗ |
| Route | Intravenous | “Faceptor 6 mg/kg IV” NCT05301010 ↗ |